AstraZeneca PLC
28 January 2004
AstraZeneca Fourth Quarter and Full Year Results 2003
Tomorrow, Thursday, 29 January 2004, AstraZeneca will be releasing Fourth
Quarter and Full Year results 2003 at 11:00gmt.
The analyst presentation at 13:00gmt will be followed by a Q&A session which can
be joined, live, via teleconference on the following numbers: UK: 0800 279 9640,
for Europe: +44 (0)207 019 9504 and for the US: 866 850 2201 . These numbers,
and details of the replay facility available through 09:00 Monday, 9 February
2004, are available on the Investor Relations part of the AstraZeneca website at
www.astrazeneca.com. A live webcast of the presentation will also be available
on this site.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.